Status:
COMPLETED
Analysis of Sexual Bias in Type 2 Innate Lymphoid Cells (ILC2) in Asthmatic Patients
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Asthma
Eligibility:
All Genders
18-45 years
Brief Summary
Asthma is more common in females than in males but the difference has not been explained yet. Group 2 innate lymphoid cells (ILC2) have recently emerged as critical players in the initiation of allerg...
Detailed Description
Asthma is more common in males until puberty but becomes more prevalent and more severe in females after puberty suggesting a protective action of male sex hormones. ILC2 have recently emerged as crit...
Eligibility Criteria
Inclusion
- Asthma according to the criteria described by Global Initiative for Asthma (GINA) guidelines
- Severe asthma according to the criteria described by the American Thoracic Society (ATS) / European Respiratory Society (ERS) guidelines (for the recruitment of severe patients)
- Mild to moderate asthma based on low or medium dose of inhaled steroids according to GINA guidelines
Exclusion
- Asthma exacerbations defined as oral corticosteroids related to worsening respiratory symptoms within the past 4 weeks
- Pregnant women
- Breastfeeding women
- Autoimmune diseases
- Androgen medication
- Early menopause defined as the absence of menstruation for at least 1 year
- Body mass index ≥ 30 kg/m²
- Weight \<40 kg
- Oral corticotherapy for more than 3 months
- Prediction of blood volume collected (care + research)\> 80 ml or\> 150 ml over a period of 30 days if blood collection within the past 30 days
- known anemia with hemoglobin \<10 g/dl
Key Trial Info
Start Date :
March 8 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 12 2023
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT04384835
Start Date
March 8 2021
End Date
April 12 2023
Last Update
June 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Larrey hospital
Toulouse, France, 31059